vs

Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

Amalgamated Financial Corp. is the larger business by last-quarter revenue ($85.2M vs $75.5M, roughly 1.1× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 9.4%). Amalgamated Financial Corp. produced more free cash flow last quarter ($134.4M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 4.3%).

CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

AMAL vs PBYI — Head-to-Head

Bigger by revenue
AMAL
AMAL
1.1× larger
AMAL
$85.2M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+18.3% gap
PBYI
27.7%
9.4%
AMAL
More free cash flow
AMAL
AMAL
$120.0M more FCF
AMAL
$134.4M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
4.3%
AMAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMAL
AMAL
PBYI
PBYI
Revenue
$85.2M
$75.5M
Net Profit
Gross Margin
69.3%
Operating Margin
39.0%
22.7%
Net Margin
Revenue YoY
9.4%
27.7%
Net Profit YoY
EPS (diluted)
$0.88
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMAL
AMAL
PBYI
PBYI
Q4 25
$85.2M
$75.5M
Q3 25
$85.6M
$54.5M
Q2 25
$80.9M
$52.4M
Q1 25
$77.0M
$46.0M
Q4 24
$77.9M
$59.1M
Q3 24
$81.0M
$80.5M
Q2 24
$78.5M
$47.1M
Q1 24
$78.3M
$43.8M
Net Profit
AMAL
AMAL
PBYI
PBYI
Q4 25
Q3 25
$26.8M
$8.8M
Q2 25
$26.0M
$5.9M
Q1 25
$25.0M
$3.0M
Q4 24
Q3 24
$27.9M
$20.3M
Q2 24
$26.8M
$-4.5M
Q1 24
$27.2M
$-4.8M
Gross Margin
AMAL
AMAL
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
AMAL
AMAL
PBYI
PBYI
Q4 25
39.0%
22.7%
Q3 25
42.9%
17.6%
Q2 25
43.8%
12.7%
Q1 25
45.1%
8.7%
Q4 24
42.4%
22.6%
Q3 24
47.2%
27.4%
Q2 24
45.6%
-4.6%
Q1 24
49.2%
-5.3%
Net Margin
AMAL
AMAL
PBYI
PBYI
Q4 25
Q3 25
31.3%
16.2%
Q2 25
32.1%
11.2%
Q1 25
32.5%
6.5%
Q4 24
Q3 24
34.5%
25.2%
Q2 24
34.1%
-9.6%
Q1 24
34.8%
-11.0%
EPS (diluted)
AMAL
AMAL
PBYI
PBYI
Q4 25
$0.88
$0.26
Q3 25
$0.88
$0.17
Q2 25
$0.84
$0.12
Q1 25
$0.81
$0.06
Q4 24
$0.78
$0.40
Q3 24
$0.90
$0.41
Q2 24
$0.87
$-0.09
Q1 24
$0.89
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMAL
AMAL
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$291.2M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$794.5M
$130.3M
Total Assets
$8.9B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMAL
AMAL
PBYI
PBYI
Q4 25
$291.2M
$97.5M
Q3 25
$115.5M
$94.4M
Q2 25
$171.1M
$96.0M
Q1 25
$65.7M
$93.2M
Q4 24
$60.7M
$101.0M
Q3 24
$149.2M
$96.7M
Q2 24
$58.0M
$96.8M
Q1 24
$155.2M
$107.2M
Total Debt
AMAL
AMAL
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
AMAL
AMAL
PBYI
PBYI
Q4 25
$794.5M
$130.3M
Q3 25
$775.6M
$115.3M
Q2 25
$754.0M
$104.7M
Q1 25
$736.0M
$97.1M
Q4 24
$707.7M
$92.1M
Q3 24
$698.2M
$71.1M
Q2 24
$646.0M
$48.5M
Q1 24
$616.8M
$51.0M
Total Assets
AMAL
AMAL
PBYI
PBYI
Q4 25
$8.9B
$216.3M
Q3 25
$8.7B
$202.9M
Q2 25
$8.6B
$194.9M
Q1 25
$8.3B
$196.2M
Q4 24
$8.3B
$213.3M
Q3 24
$8.4B
$220.7M
Q2 24
$8.3B
$205.0M
Q1 24
$8.1B
$214.1M
Debt / Equity
AMAL
AMAL
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMAL
AMAL
PBYI
PBYI
Operating Cash FlowLast quarter
$135.8M
$14.4M
Free Cash FlowOCF − Capex
$134.4M
$14.4M
FCF MarginFCF / Revenue
157.8%
19.1%
Capex IntensityCapex / Revenue
1.6%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$229.4M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMAL
AMAL
PBYI
PBYI
Q4 25
$135.8M
$14.4M
Q3 25
$39.5M
$9.7M
Q2 25
$24.9M
$14.1M
Q1 25
$34.2M
$3.6M
Q4 24
$124.1M
$15.6M
Q3 24
$35.8M
$11.0M
Q2 24
$28.0M
$1.0M
Q1 24
$31.3M
$11.2M
Free Cash Flow
AMAL
AMAL
PBYI
PBYI
Q4 25
$134.4M
$14.4M
Q3 25
$38.3M
$9.7M
Q2 25
$24.2M
$14.1M
Q1 25
$32.5M
$3.6M
Q4 24
$122.3M
$15.6M
Q3 24
$35.2M
$11.0M
Q2 24
$27.8M
$1.0M
Q1 24
$31.1M
FCF Margin
AMAL
AMAL
PBYI
PBYI
Q4 25
157.8%
19.1%
Q3 25
44.7%
17.7%
Q2 25
29.9%
26.8%
Q1 25
42.2%
7.7%
Q4 24
157.0%
26.4%
Q3 24
43.4%
13.7%
Q2 24
35.4%
2.1%
Q1 24
39.7%
Capex Intensity
AMAL
AMAL
PBYI
PBYI
Q4 25
1.6%
0.0%
Q3 25
1.4%
0.0%
Q2 25
0.9%
0.0%
Q1 25
2.3%
0.1%
Q4 24
2.3%
0.0%
Q3 24
0.7%
0.0%
Q2 24
0.3%
0.0%
Q1 24
0.3%
0.0%
Cash Conversion
AMAL
AMAL
PBYI
PBYI
Q4 25
Q3 25
1.47×
1.10×
Q2 25
0.96×
2.41×
Q1 25
1.37×
1.21×
Q4 24
Q3 24
1.28×
0.54×
Q2 24
1.05×
Q1 24
1.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons